Development of a tool to assess HIV prevention readiness of adolescent girls and young women in HPTN 082 study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
25
03
2022
accepted:
25
01
2023
entrez:
24
2
2023
pubmed:
25
2
2023
medline:
3
3
2023
Statut:
epublish
Résumé
African adolescent girls and young women (AGYW) represent a large proportion of new HIV infections, a priority population for pre-exposure prophylaxis (PrEP), but adherence remains a challenge. A reliable, valid readiness tool would help identify AGYW motivated to take PrEP who need adherence support. In the HPTN 082 open-label PrEP study (2016-2019), South African and Zimbabwean women ages 16-25 were administered an HIV prevention readiness measure (HPRM). The 25 items in the HPRM included medication beliefs, connection with care, disclosure of PrEP use, social support, and housing stability using a 5-point Likert scale. Exploratory factor analysis (EFA) using polychoric correlations, scale reliability, and predictive validity were performed on data from 315 participants who responded to all items. We assessed the predictive value of HPRM scores with PrEP adherence, defined as tenofovir-diphosphate (TFV-DP) concentrations in dried blood spots, as a continuous measure and dichotomized as high PrEP adherence (≥700 fmol/punch). EFA yielded 23 items with three subscales: self-efficacy (16 items), PrEP disclosure (4 items), and social support (3 items). Cronbach's α ranged from 0.71 to 0.92 for the overall scale and the subscales. The average overall scale and the subscales were predictive of 3-month PrEP adherence for TFV-DP concentrations: for each unit increase of the HPRM score, TFV-DP concentration increased by 103 fmol/punch (95% CI: 16, 189, p = 0.02); the highest HPRM score equated with 608 fmol/punch on average. For the self-efficacy subscale, TFV-DP increased by 90 fmol/punch (95% CI: 7, 172, p = 0.03); PrEP disclosure, 68 fmol/punch (95% CI: 19, 117 p = 0.01); and social support, 58fmol/punch (95% CI: 2, 113, p = 0.04). Higher PrEP disclosure suggests high adherence (OR 1.36, 95% CI: 1.00, 1.86, p = 0.05) and predicted persistent high adherence at both months three and six (OR: 1.50, 95% CI: 1.03, 2.21, p = 0.04). The HPRM scale overall and the subscales individually demonstrated good internal consistency among African young women. PrEP disclosure subscale exhibiting significant association with persistent high PrEP adherence is an important finding for PrEP adherence support programs. Future work will assess replicability and expand self-efficacy and social-support subscales after item revision. ClinicalTrials.gov NCT02732730.
Sections du résumé
BACKGROUND
African adolescent girls and young women (AGYW) represent a large proportion of new HIV infections, a priority population for pre-exposure prophylaxis (PrEP), but adherence remains a challenge. A reliable, valid readiness tool would help identify AGYW motivated to take PrEP who need adherence support.
METHODS
In the HPTN 082 open-label PrEP study (2016-2019), South African and Zimbabwean women ages 16-25 were administered an HIV prevention readiness measure (HPRM). The 25 items in the HPRM included medication beliefs, connection with care, disclosure of PrEP use, social support, and housing stability using a 5-point Likert scale. Exploratory factor analysis (EFA) using polychoric correlations, scale reliability, and predictive validity were performed on data from 315 participants who responded to all items. We assessed the predictive value of HPRM scores with PrEP adherence, defined as tenofovir-diphosphate (TFV-DP) concentrations in dried blood spots, as a continuous measure and dichotomized as high PrEP adherence (≥700 fmol/punch).
RESULTS
EFA yielded 23 items with three subscales: self-efficacy (16 items), PrEP disclosure (4 items), and social support (3 items). Cronbach's α ranged from 0.71 to 0.92 for the overall scale and the subscales. The average overall scale and the subscales were predictive of 3-month PrEP adherence for TFV-DP concentrations: for each unit increase of the HPRM score, TFV-DP concentration increased by 103 fmol/punch (95% CI: 16, 189, p = 0.02); the highest HPRM score equated with 608 fmol/punch on average. For the self-efficacy subscale, TFV-DP increased by 90 fmol/punch (95% CI: 7, 172, p = 0.03); PrEP disclosure, 68 fmol/punch (95% CI: 19, 117 p = 0.01); and social support, 58fmol/punch (95% CI: 2, 113, p = 0.04). Higher PrEP disclosure suggests high adherence (OR 1.36, 95% CI: 1.00, 1.86, p = 0.05) and predicted persistent high adherence at both months three and six (OR: 1.50, 95% CI: 1.03, 2.21, p = 0.04).
CONCLUSIONS
The HPRM scale overall and the subscales individually demonstrated good internal consistency among African young women. PrEP disclosure subscale exhibiting significant association with persistent high PrEP adherence is an important finding for PrEP adherence support programs. Future work will assess replicability and expand self-efficacy and social-support subscales after item revision.
TRIAL REGISTRATION
ClinicalTrials.gov NCT02732730.
Identifiants
pubmed: 36827440
doi: 10.1371/journal.pone.0281728
pii: PONE-D-22-06924
pmc: PMC9956790
doi:
Substances chimiques
Anti-HIV Agents
0
tenofovir diphosphate
0
Banques de données
ClinicalTrials.gov
['NCT02732730']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0281728Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI068613
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069463
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068619
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069436
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069436
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068617
Pays : United States
Informations de copyright
Copyright: © 2023 Beauchamp et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
I have read the journal’s policy and the authors of this manuscript have the following competing interests: PLA reports grants from Gilead; and consulting fees from Gilead, Merck, and ViiV Healthcare. CC reports grants to her institution from the NIH and the Bill & Melinda Gates Foundation; consulting fees from Merck and Gilead as a scientific advisor; payments for expert testimony and support for attending meetings from Gilead; and donated drugs from Gilead. CC also participates on data safety monitoring boards and advisory boards for the HIV Prevention Trials Network and the London School of Hygiene & Tropical Medicine (London, UK).
Références
N Engl J Med. 2015 Feb 5;372(6):509-18
pubmed: 25651245
AIDS Behav. 2015 May;19(5):784-93
pubmed: 25416076
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29038282
J Acquir Immune Defic Syndr. 2014 Aug 15;66 Suppl 3:S250-8
pubmed: 25007194
Curr HIV/AIDS Rep. 2021 Dec;18(6):490-499
pubmed: 34719745
Medicine (Baltimore). 2019 Oct;98(43):e17716
pubmed: 31651904
AIDS Behav. 2020 Jul;24(7):2149-2162
pubmed: 31955361
PLoS One. 2020 Jan 13;15(1):e0226062
pubmed: 31929547
J Int AIDS Soc. 2014 Sep 08;17(3 Suppl 2):19146
pubmed: 25224610
N Engl J Med. 2012 Aug 2;367(5):411-22
pubmed: 22784040
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
Psychol Bull. 1992 May;111(3):455-74
pubmed: 1594721
J Health Psychol. 2011 Oct;16(7):1071-81
pubmed: 21459919
AIDS Res Hum Retroviruses. 2013 Feb;29(2):384-90
pubmed: 22935078
AIDS Care. 2011 Nov;23(11):1492-9
pubmed: 22022853
J Assoc Nurses AIDS Care. 2018 Nov - Dec;29(6):835-848
pubmed: 29685648
J Int AIDS Soc. 2016 Dec 12;19(1):21134
pubmed: 27964776
Sci Transl Med. 2012 Sep 12;4(151):151ra125
pubmed: 22972843
PLoS Med. 2021 Jun 18;18(6):e1003670
pubmed: 34143779
Vulnerable Child Youth Stud. 2019;14(2):142-150
pubmed: 32863849
J Agromedicine. 2017;22(4):295-297
pubmed: 28742433
Pediatrics. 2020 Jan;145(1):
pubmed: 31857381
AIDS Behav. 2018 Nov;22(11):3603-3616
pubmed: 29557540
AIDS. 2013 Aug 24;27(13):2155-60
pubmed: 24384592
Behav Res Methods. 2020 Dec;52(6):2306-2323
pubmed: 32333330
Lancet. 2013 Jun 15;381(9883):2083-90
pubmed: 23769234
J Strength Cond Res. 2005 Feb;19(1):231-40
pubmed: 15705040
Front Public Health. 2018 Jun 11;6:149
pubmed: 29942800
Lancet Infect Dis. 2014 Sep;14(9):820-9
pubmed: 25065857
J Int AIDS Soc. 2020 Mar;23(3):e25463
pubmed: 32144874
J Int AIDS Soc. 2019 Feb;22(2):e25223
pubmed: 30768776
Lancet HIV. 2018 Feb;5(2):e68-e78
pubmed: 28986029
Med Care. 1986 Jan;24(1):67-74
pubmed: 3945130
PLoS One. 2021 Oct 14;16(10):e0258542
pubmed: 34648589
AIDS Behav. 2021 Jul;25(7):2154-2165
pubmed: 33521908
AIDS. 2016 Jul 31;30(12):1973-83
pubmed: 27149090